It was announced today that Sweden-based Calliditas Therapeutics AB has signed a license agreement with Everest Medicines II Limited, a company that develops novel transformative pharmaceutical therapies for patients in the Emerging Market including Asia Pacific territories.
The contract has been signed to develop and commercialise Calliditas Therapeutics AB's leading drug candidate Nefecon in Greater China and Singapore for the chronic autoimmune kidney disease IgA Nephropathy.
According to the terms of the contract, Calliditas will receive an initial upfront payment of USD15m on signing, with future payments expected up to an additional USD106m, including an option worth up to USD20m for the development of Nefecon in other potential indications.
Everest will also pay typical royalties on net sales.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca